SEC Comment Letter 0000000000-24-001482 to Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284) (OLMA)
Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284)
Date: Feb. 7, 2024 · CIK: 0001750284 · Accession: 0000000000-24-001482
AI Filing Summary & Sentiment
File numbers found in text: 333-276787
Letter
United States securities and exchange commission logo February 7, 2024 Sean Bohen Chief Executive Officer Olema Pharmaceuticals, Inc. 780 Brannan Street San Francisco, CA 94103 Re:Olema Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 31, 2024 File No. 333-276787 Dear Sean Bohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Julia Boesch, Esq.
Show Raw Text
United States securities and exchange commission logo
February 7, 2024
Sean Bohen
Chief Executive Officer
Olema Pharmaceuticals, Inc.
780 Brannan Street
San Francisco, CA 94103
Re:Olema Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 31, 2024
File No. 333-276787
Dear Sean Bohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Julia Boesch, Esq.